Table 3.

Comparison of survival between the groups based on adjusted HR estimates

(a) Comparison of survival between the groups in overall Stage I–III BC population using adjusted HR estimates
Groups; days from surgery to start of AC	Adjusted HR	95% CI
31–60 vs ≤ 30	0.842	0.814	0.870
31–60 vs 61–90	0.900	0.867	0.935
31–60 vs 91–120	0.802	0.754	0.852
31–60 vs > 120	0.710	0.661	0.763
61–90 vs ≤ 30	0.935	0.896	0.976
61–90 vs 91–120	0.891	0.834	0.952
61–90 vs > 120	0.789	0.731	0.852
91–120 vs ≤ 30	1.050	0.984	1.119
91–120 vs > 120	0.886	0.809	0.969
≤ 30 vs > 120	0.844	0.783	0.909

(b) Comparison of survival between the various groups in TNBC patients using adjusted HR estimates
Groups; days from surgery to start of AC	Adjusted HR	95% CI
31–60 vs ≤ 30	0.816	0.772	0.863
31–60 vs 61–90	0.892	0.833	0.956
31–60 vs 91–120	0.791	0.705	0.887
31–60 vs > 120	0.777	0.673	0.898
61–90 vs ≤ 30	0.915	0.849	0.986
61–90 vs 91–120	0.887	0.783	1.004
61–90 vs > 120	0.871	0.748	1.015
91–120 vs ≤ 30	1.032	0.917	1.161
91–120 vs > 120	0.983	0.823	1.174
≤ 30 days vs > 120	0.952	0.822	1.104

(c) Adjusted HR estimates with survival comparison in hormone positive/HER2 negative BC patients
Groups; days from surgery to start of AC	Adjusted HR	95% CI
31–60 vs ≤ 30	0.846	0.805	0.890
31–60 vs 61–90	0.967	0.916	1.020
31–60 vs 91–120	0.864	0.793	0.940
31–60 vs > 120	0.725	0.657	0.799
61–90 vs ≤ 30	0.875	0.822	0.932
61–90 vs 91–120	0.893	0.814	0.980
61–90 vs > 120	0.750	0.675	0.832
91–120 vs ≤ 30	0.980	0.895	1.073
91–120 vs > 120	0.839	0.742	0.949
≤ 30 vs > 120	0.856	0.773	0.949

(d) Adjusted HR for hormone positive/HER2 positive and hormone negative/HER2 positive BC patients comparing survival outcomes
Groups in days	Hormone positive/HER2 positive BC			Hormone negative/HER2 positive BC
	HR	95% CI		HR	95% CI
31–60 vs ≤ 30	0.854	0.772	0.944	0.840	0.741	0.952
31–60 vs 61–90	0.811	0.728	0.904	0.771	0.672	0.885
31–60 vs 91–120	0.680	0.576	0.803	0.904	0.708	1.155
31–60 vs > 120	0.562	0.463	0.681	0.721	0.544	0.954
61–90 vs ≤ 30	1.052	0.928	1.192	1.089	0.932	1.272
61–90 vs 91–120	0.839	0.700	1.004	1.172	0.903	1.522
61–90 vs > 120	0.692	0.564	0.850	0.934	0.696	1.254
91–120 vs ≤ 30	1.254	1.051	1.498	0.929	0.720	1.199
91–120 vs >120	0.825	0.649	1.049	0.797	0.557	1.139
≤ 30 vs >120	0.658	0.538	0.805	0.858	0.642	1.146

BC breast cancer; AC adjuvant chemotherapy; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer; CI confidence interval; HR hazard ratio